Transcriptomic Profiling Pre- and Post-Dupilumab Treatment in Atopic Dermatitis Using Minimally Invasive Microneedle Sampling: A Pilot Study
Year: 2026
Type: article
Abstract: Individual differences in dupilumab treatment response remain an unmet need. This pilot study aimed to explore transcriptomic changes and candidate molecular signals that may reflect disease activity and treatment response by analyzing gene expression changes in patients with atopic dermatitis (AD) using a minimally invasive microneedle-based skin sampling method (MISSM). Lesional and non-lesional skin samples were collected from six patients with moderate to severe AD before and 16 weeks after dupilumab treatment, and only samples exceeding a predefined complementary RNA (cRNA) yield threshold following pico-scale RNA amplification were analyzed by microarray. Transcriptome profiling identified several genes, including immunoglobulin variable-region and T-cell receptor genes, that showed correlation trends with clinical improvement (change in Eczema Area and Severity Index, ΔEASI) and significant changes after treatment in the responder group. Baseline expression of other immune-related genes, such as chemokines and immunoglobulins, differed between responders and non-responders. As these findings were derived from a small, non-independent cohort, they should be regarded as exploratory signals rather than validated biomarkers. We also demonstrated that MISSM is a feasible platform for multi-layered analysis of molecular changes in AD, supporting its potential utility for longitudinal treatment response monitoring and molecular profiling in chronic inflammatory skin disease.
Institution: National Medical Center
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7225860668
